Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Natural history of multiple sclerosis: have available therapies impacted long-term prognosis?

Trojano M, Paolicelli D, Tortorella C, Iaffaldano P, Lucchese G, Di Renzo V, D'Onghia M.

Neurol Clin. 2011 May;29(2):309-21. doi: 10.1016/j.ncl.2010.12.008. Review.

PMID:
21439443
2.

Disease-modifying agents in the treatment of multiple sclerosis: a review of long-term outcomes.

Katrych O, Simone TM, Azad S, Mousa SA.

CNS Neurol Disord Drug Targets. 2009 Dec;8(6):512-9. Review.

PMID:
19811446
3.

Postmarketing evidence of disease-modifying drugs in multiple sclerosis.

Trojano M, Paolicelli D, Fuiani A, Pellegrini F, Iaffaldano P, Direnzo V, D'Onghia M.

Neurol Sci. 2008 Sep;29 Suppl 2:S225-6. doi: 10.1007/s10072-008-0944-z. Review.

PMID:
18690499
4.

[Long-term effects of glatiramer acetate in multiple sclerosis].

Brochet B.

Rev Neurol (Paris). 2008 Nov;164(11):917-26. doi: 10.1016/j.neurol.2008.02.045. Epub 2008 May 16. French.

PMID:
18790510
5.

The search for a balance between short and long-term treatment outcomes in multiple sclerosis.

Baumhackl U.

J Neurol. 2008 Mar;255 Suppl 1:75-83. doi: 10.1007/s00415-008-1010-8. Review.

PMID:
18317679
6.

Clinical trials of multiple sclerosis therapies: improvements to demonstrate long-term patient benefit.

Carroll WM.

Mult Scler. 2009 Aug;15(8):951-8. doi: 10.1177/1352458509105426. Epub 2009 May 22. Review.

PMID:
19465446
7.

Modern multiple sclerosis treatment - what is approved, what is on the horizon.

Pilz G, Wipfler P, Ladurner G, Kraus J.

Drug Discov Today. 2008 Dec;13(23-24):1013-25. doi: 10.1016/j.drudis.2008.08.003. Epub 2008 Sep 25. Review.

PMID:
18775508
8.

What is new in the treatment of multiple sclerosis?

Weinstock-Guttman B, Jacobs LD.

Drugs. 2000 Mar;59(3):401-10. Review.

PMID:
10776827
9.

Link of the mechanisms of action of glatiramer acetate to its long-term clinical data.

Moreau T.

J Neurol Sci. 2009 Feb 1;277 Suppl 1:S12-5. doi: 10.1016/S0022-510X(09)70005-X. Review.

PMID:
19200858
10.

Long-term follow-up of clinical trials of multiple sclerosis therapies.

Freedman MS.

Neurology. 2011 Jan 4;76(1 Suppl 1):S26-34. doi: 10.1212/WNL.0b013e318205051d. Review.

PMID:
21205679
11.

Treatment of pediatric multiple sclerosis and variants.

Pohl D, Waubant E, Banwell B, Chabas D, Chitnis T, Weinstock-Guttman B, Tenembaum S; International Pediatric MS Study Group.

Neurology. 2007 Apr 17;68(16 Suppl 2):S54-65. Review.

PMID:
17438239
12.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
13.

Current approved options for treating patients with multiple sclerosis.

Rizvi SA, Agius MA.

Neurology. 2004 Dec 28;63(12 Suppl 6):S8-14. Review.

PMID:
15623672
14.

The gap between effect of drugs and effectiveness of treatments.

Sorensen PS.

J Neurol Sci. 2007 Aug 15;259(1-2):128-32. Epub 2007 Mar 23. Review.

PMID:
17362994
15.

New options for early treatment of multiple sclerosis.

Tintoré M.

J Neurol Sci. 2009 Feb 1;277 Suppl 1:S9-S11. doi: 10.1016/S0022-510X(09)70004-8. Review.

PMID:
19200870
16.

Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials.

Bates D.

Neurology. 2011 Jan 4;76(1 Suppl 1):S14-25. doi: 10.1212/WNL.0b013e3182050388. Review.

PMID:
21205678
17.

Rationale for early intervention with immunomodulatory treatments.

Tintoré M.

J Neurol. 2008 Mar;255 Suppl 1:37-43. doi: 10.1007/s00415-008-1006-4. Review.

PMID:
18317675
18.

Management of worsening multiple sclerosis with mitoxantrone: a review.

Fox EJ.

Clin Ther. 2006 Apr;28(4):461-74. Review.

PMID:
16750460
19.

Multiple sclerosis: interferon beta for some serious forms.

[No authors listed]

Prescrire Int. 2007 Dec;16(92):252-7.

PMID:
18092425
20.

Influence of treatment in multiple sclerosis disability: an open, retrospective, non-randomized long-term analysis.

Werneck LC, Lorenzoni PJ, Radünz VA, Utiumi MA, Kay CS, Scola RH.

Arq Neuropsiquiatr. 2010 Aug;68(4):511-21.

Supplemental Content

Support Center